Dr. AeRang Kim, MD, PhD
Claim this profileChildren's National Medical Center
Expert in Tumors
Studies Sarcoma
20 reported clinical trials
32 drugs studied
About AeRang Kim, MD, PhD
Education:
- BA from Northwestern University, 1996.
- MD from the University of Illinois, Chicago, 2001.
- PhD in Public Health from Johns Hopkins University School of Public Health, 2009.
Experience:
- Completed Internship in Pediatrics at New York Hospital, 2002.
- Finished Residency in Pediatrics at New York University, 2004.
- Undertook Fellowship in Pediatric Hematology-Oncology at Johns Hopkins Hospital, 2008.
- Currently a solid tumor faculty member at Children's National Hospital and an Associate Professor of Pediatrics, with a specialization in sarcomas and developmental therapeutics.
Area of expertise
1Tumors
Global LeaderStage IV
NTRK1 positive
NTRK positive
2Sarcoma
Stage IV
EWSR1-FLI1 translocation positive
EWS rearrangement positive
Affiliated Hospitals
Clinical Trials AeRang Kim, MD, PhD is currently running
APG-115 + Pembrolizumab
for Skin Cancer
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Recruiting1 award Phase 1 & 213 criteria
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
More about AeRang Kim, MD, PhD
Clinical Trial Related6 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments AeRang Kim, MD, PhD has experience with
- Temozolomide
- Ramucirumab
- Cyclophosphamide
- Vinorelbine
- Docetaxel
- Gemcitabine
Breakdown of trials AeRang Kim, MD, PhD has run
Tumors
Sarcoma
Solid Tumors
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does AeRang Kim, MD, PhD specialize in?
AeRang Kim, MD, PhD focuses on Tumors and Sarcoma. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are NTRK1 positive.
Is AeRang Kim, MD, PhD currently recruiting for clinical trials?
Yes, AeRang Kim, MD, PhD is currently recruiting for 8 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that AeRang Kim, MD, PhD has studied deeply?
Yes, AeRang Kim, MD, PhD has studied treatments such as Temozolomide, Ramucirumab, Cyclophosphamide.
What is the best way to schedule an appointment with AeRang Kim, MD, PhD?
Apply for one of the trials that AeRang Kim, MD, PhD is conducting.
What is the office address of AeRang Kim, MD, PhD?
The office of AeRang Kim, MD, PhD is located at: Children's National Medical Center, Washington, District of Columbia 20010 United States. This is the address for their practice at the Children's National Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.